Panobinostat (LBH589)

製品コードS1030 別名:NVP-LBH589

Panobinostat (LBH589)化学構造

分子量(MW):349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

サイズ 価格(税別)  
JPY 14940.00
JPY 44820.00
JPY 111220.00

文献中Selleckの製品使用例(48)

カスタマーフィードバック(12)

  • (G) A375 parental and BRAFi-resistant ex vivo clones were treated with a panel of HDACi (1 μM vorinostat, 0.5 μM belinostat, and 6 nM panobinostat) in single treatment or in combination with 1 μM vemurafenib in a long-term colony formation assay.

    Cell, 2018, 173(6):1413-1425. Panobinostat (LBH589) purchased from Selleck.

    LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Panobinostat (LBH589) purchased from Selleck.

  • Using CRISPR-Cas9 technology, ERα was silenced at the genomic level in ECC1 cells. Ishikawa, parental ECC1 cells and individual ESR1 KO ECC1 clones were treated with 20 nM LBH589 for 24 hr. Expression of ERα, PR, FOXO1, and Myc were evaluated by Western blotting. β-actin serves as a loading control.

    PLoS One, 2016, 11(2):e0148912.. Panobinostat (LBH589) purchased from Selleck.

    HDACIs That Simultaneously Inhibit HDACs 1 and 6 Showed Greater Antileukemic Activities than HDACIs that Don’t at Cmax Concentrations. THP-1 cells were treated with LBH-589, PXD101, SAHA, VPA, MS-275 and MGCD0103 at Cmax concentrations for 3 h and 24 h, respectively. The cells post 3 h treatments were washed three times with complete medium and divided into two halves. One half of the cells was resuspended in complete media and cultured for up to 24 h to determine the effects of the 3 h treatments on cell proliferation and apoptosis. The other half of the cells was used to prepare whole cell lysates. Whole cell lysates from the 3 h and 24 h treatments were extracted and subjected to Western blots probed by anti-ac-tubulin or –b-actin antibody (panels A&B), or subjected to HDAC1 enzymatic assays post IP as described in the Materials and Methods (Panels C&D). The effects of the 3 h and 24 h HDACI treatments on cell proliferation, as reflected by percent decrease of live cells relative to untreated cells (panel E), and apoptosis (panel F) were determined by flow cytometry analysis as described in the Materials and Methods.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

  • Induction of DNA Damage and Bim Is Critical for HDACI-Induced Apoptosis in Pediatric AML Cells. THP-1 cells were treated with the HDACIs at Cmax concentrations for 3 (panel A) and 24 h (panel B), respectively. Whole cell lysates were extracted and subjected to Western blots probed by anti-p21, -c-Myc, -cH2AX, -Bim, or -b-actin antibody.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

    Cell death induction by LBH589 as a single agent was detected in control or MTDH knockdown Hec50co cells. After 3 days, cell death was determined by the WST-1 method.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

  • Expression of pro-/anti-apoptosis genes. Control or MTDH knockdown Hec50co cells were treated for 24 hours with vehicle control, 20 nM LBH589, 25 ng/ml TRAIL or LBH589 and TRAIL at the concentrations noted. Lysates were collected. Expression of DR4, DR5, and apoptosis related caspase-3, caspase-8, PARP-1, BID, FLIP, XIAP, Bim, MCL-1 and BCL-XL was analyzed by Western blotting.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

    p53(+/+) and (/) HCT116 cells were treated with TSA (1–5 lM),LBH589 (2–5 lM), valproate (2.5–5 mM), MS-275 (20 lM) and sodium butyrate (2 mM). TAp63 expression was compared in both cell lines after 24 h of treatment. Consistent with the above data, all HDAC inhibitors failed to induce significant levels of TAp63 in p53(/) HCT116 cells.

     

     

    Biochem Bioph Res Co 2009 391, 1748-1751. Panobinostat (LBH589) purchased from Selleck.

  • Effect of panobinostat on the viability of cervical cancer cells. HeLa (A) and SiHa (B) cells were treated with increasing concentrations of panobinostat for 24, 48 and 72 h. Cell viability was determined by MTT assay. The results are presented as percentage; calculated from the reduction in cell viability at a given concentration of drug compared to the untreated control (untreated control being 100%). The IC5072h values were calculated from sigmoidal dose-response curves generated in Prism 5.0 (GraphPad). (C) Cytotoxic effects of panobinostat on HeLa and SiHa cells measured at 72 h and expressed as% cell death. Each value is the mean ± SD of three independent experiments performed in triplicates.

    Biomed Pharmacother, 2016, 84:1393-1405. Panobinostat (LBH589) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-10μM Panobinostat was added.

    Dr.Zhang of Tianjin Medical University. Panobinostat (LBH589) purchased from Selleck.

  • HDAC inhibitors induce p63a expression (A) HCT116 cells were treated with TSA (1 lM), LBH589 (2 lM), valproate (2.5 mM), MS-275 (20 lM) and sodium butyrate(2 mM) for 24 h. Expression of p63 was assessed by Western blotting with the H129 pan-anti-p63 antibody. Although TSA and LBH589 induced p63 efficiently, valproate, MS-275 and sodium butyrate were much less efficient. The lower panel shows the actin loading control. Arrow indicates TAp63. (B) The HDAC inhibitors used in this study are shown, grouped according to their structure and with their HDAC specificity. The efficiency of TAp63 expression is shown in the last column.

     

     

    Dr. Berna S. Sayan of Leicester University. Panobinostat (LBH589) purchased from Selleck.

    U266 and KMS-11 were treated with 20 nM panobinostat for 48 h followed by Western blot analysis. Actin served as a loading control. Nine (U266) and 3 (KMS-11) biologically independent experiments were performed. To determine the expression of PPP3CA mRNA in treated cells for 24 h, we performed relative quantification real-time PCR (n = 6). Four (U266) and 2 (KMS-11) biologically independent experiments were performed.

    JCI Insight, 2016, 1(5):e85061. Panobinostat (LBH589) purchased from Selleck.

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
ターゲット
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
体外試験

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 NEK3OXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPkXIsxNTFyIN88US=> MVewMVQh\A>? MXjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWmyOlcxOjd6NB?=
HepG2 MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{i5[VAuOTBizszN NFjX[|QxNTRiZB?= NEjCTm1qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M1\SbFI3PzB{N{i0
HT29 MWrGeY5kfGmxbjDBd5NigQ>? NXLySWNkPTEEoH7N NEjRTZEzPC15MjDo M1;UUYlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhPDkEoHlCpC=> MoPINlY4ODJ5OES=
HepG2 Mk\MSpVv[3Srb36gRZN{[Xl? NIruUZk2OMLibl2= M{C4PVI1NTd{IHi= M4TPZYlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhOjUEoHlCpC=> NGC1SmIzPjdyMke4OC=>
HCC827 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWK1M|cvPS9zMDDuUS=> NV73dGcxPzMEoHi= MlnGSG1UVw>? NH6xfnlmdmijbnPld{B1cGViYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1KG:oIHXycI91cW6rYh?= MnH3NlY3PzV2OES=
A549  Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVixNE8yPS9{MDDuUS=> M33GfVczyqCq MV\EUXNQ NVyxb49O\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK= NYPLXohkOjZ4N{W0PFQ>
NCI-H460  M1iwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;5TVkyOC9{MD:zNEBvVQ>? NVzRRlNoPzMEoHi= MVzEUXNQ MXPlcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>? NVLBVZJ5OjZ4N{W0PFQ>
J89GFP M2jLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvEUXNQyqB? MWHFR|UxRTR7Lki1JOKyKDF{Lk[1JI5O MUeyOlU3OzV4OB?=
THP89GFP M3r0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHEUXNQyqB? NGf0NXdGSzVyPUG5MlM1KMLzIE[uOFMhdk1? Mm\RNlY2PjN3Nki=
SK-NEP-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT0VVMxNjBz4pETNVAvOCEQvF2= Mlv3NlQhcA>? M1;XPGROW00EoB?= NF74eIJKSzVyPUe2MlM1KG6P NXPnUVc{OjZzN{[yNVk>
G401 M3fNd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXuwOI43OC5yMfMAl|ExNjBizszN NWG4TXBVOjRiaB?= NEXHfYJFVVORwrC= Mo\1TWM2OD1zNEOuNFIhdk1? NVrJWoZTOjZzN{[yNVk>
SK-NEP-1 NHjsZXlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NX7rNWQxPTBibl2= NF:wPWQy6oDVNDDk NV;BWGU1TE2VT9Mg NXfz[45qemWmdXPld{Bk\WyuIIP1dpZqfmGuIHnuJIEhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ NG[2O40zPjF5NkKxPS=>
G401 Ml\pR4VtdCCYaXHibYxqfHliQYPzZZk> Ml;jOVAhdk1? MWCx5qCUPCCm NUn5O|BrTE2VT9Mg NWrJeWNCemWmdXPld{Bk\WyuIIP1dpZqfmGuIHnuJIEhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ MlXQNlYyPzZ{MUm=
SK-NEP-1 M17UeWFxd3C2b4Ppd{BCe3OjeR?= MnjiOVAwOTByIH7N M4nGR|I1KGh? NFzFSGdFVVORwrC= MWnpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnLxNlYyPzZ{MUm=
G401 NWHZW5ZrSXCxcITvd4l{KEG|c3H5 MknvOVAwOTByIH7N NEW2NFYzPCCq M3j0c2ROW00EoB?= MkT6bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlHpNlYyPzZ{MUm=
SK-NEP-1 M2fRTGZ2dmO2aX;uJGF{e2G7 M3jFOlUxNzFyMDDuUS=> MnL3NlQhcA>? MlHTSG1UV8Li M{XWTJNpd3e|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25? MVKyOlE4PjJzOR?=
G401 MkTuSpVv[3Srb36gRZN{[Xl? M1e2WVUxNzFyMDDuUS=> NHf0OnMzPCCq M2\jeWROW00EoB?= NHHV[|d{cG:5czD0bIUhcW6mdXP0bY9vKG:oIFTORUBnemGpbXXueIF1cW:w Mo\rNlYyPzZ{MUm=
SK-NEP-1 NYj6eVF2TnWwY4Tpc44hSXO|YYm= NXzEbY9{PTBxMUCwJI5O MWOyOEBp MnrpSG1UV8Li NGjvZ5FqdmS3Y3XzJINmdGxiY4njcIUh\Gm|b4Lk[ZLDqA>? MnTyNlYyPzZ{MUm=
G401 NYHaUGpkTnWwY4Tpc44hSXO|YYm= MnzQOVAwOTByIH7N MUGyOEBp MVjEUXNQyqB? NETGZ4lqdmS3Y3XzJINmdGxiY4njcIUh\Gm|b4Lk[ZLDqA>? NVj4OJc5OjZzN{[yNVk>
RPMI 8226 MXXD[YxtKFO3co\peoFtKEG|c3H5 NXzsPJlkOi92L{[gcm0> NH\ZWoU1QOLCiXi= M2PMOolv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? Mmi2NlYxODB{OUK=
OPM2 MX\D[YxtKFO3co\peoFtKEG|c3H5 NFXXUW8zNzRxNjDuUS=> M3LOfFQ56oDLaB?= MXzpcoR2[2W|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp NXr1XJpxOjZyMECyPVI>
U266 MUPD[YxtKFO3co\peoFtKEG|c3H5 NF7PXFkzNzRxNjDuUS=> MWC0PQKBkWh? NVXUbZNPcW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= NVvTWGNTOjZyMECyPVI>
H929 NVnaWox5S2WubDDTeZJ3cX[jbDDBd5NigQ>? M1[0WFIwPC94IH7N NXX3WWRmPDkkgJno M4PxWolv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? MlHUNlYxODB{OUK=
RPMI 8226  M4n5d2Fxd3C2b4Ppd{BCe3OjeR?= MX205qCKdk1? MVWyOE81QCCq M2Dw[Ylv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MViyOlAxODJ7Mh?=
HCC827 NUTTc|dIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfp[m01OTBibl2= MWS0PEBp NUewd4g1TE2VTx?= NXjBTYMz\W6qYX7j[ZMh[2m|cHzheIlvKHOnboPpeIl3cXS7wrC= NUm2dms2OjV7NES2NVc>
NCI-H23 MnHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVuxNEBvVQ>? NGCxXoc1QCCq NYPORWRwTE2VTx?= NFPHfZVmdmijbnPld{BkcXOybHH0bY4he2Wwc3n0bZZqfHoEoB?= NIrrUJQzPTl2NE[xOy=>
AML3 M3rNT2Z2dmO2aX;uJGF{e2G7 NYrqWoptOC1zIN88US=> M3[5XlI1yqCq M2HKOIlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M{C5bVI2PjF{OUSx
ML-1 M4nqW2Z2dmO2aX;uJGF{e2G7 M4TqRVAuOSEQvF2= M3TYfFI1yqCq MlHYbY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NYfiTG17OjV4MUK5OFE>
RPMI-8226vr10  MmTxSpVv[3Srb36gRZN{[Xl? Ml7BNE0yKM7:TR?= MnnhNlTDqGh? MmTPbY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGTk[|IzPTZzMkm0NS=>
ML-1 MmjmSpVv[3Srb36gRZN{[Xl? M124WFEh|ryP MYCyOOKhcA>? M1OwRolv[3KnYYPld{Bk[XOyYYPlMVMh[WO2aY\peJkhPC2ob3zk NHvqToYzPTZzMkm0NS=>
RPMI-8226vr10  NF7tfVdHfW6ldHnvckBCe3OjeR?= MWOxJO69VQ>? MUOyOOKhcA>? MlHrbY5kemWjc3XzJINie3Cjc3WtN{Bi[3Srdnn0fUAzNjVvZn;s[C=> NXvJPFZlOjV4MUK5OFE>
SK-N-BE (2) M2flbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWWyOQKBkWh? M2f6T2lEPTB;MUC0MlDjiIoEsfMAjVcvQCCwTR?= MlfaNlU{ODh7MU[=
SK-N-BE (2), PAN  MK NYP6cG16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXuPYF6OjUkgJno Mn;PTWM2OD1zMESuNQKBkcLz4pEJO{45KG6P M1\TZVI2OzB6OUG2
SK-N-BE (2), MK  PAN MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnhOWlQOjUkgJno MVLJR|UxRTN6Mj6w5qCKyrIkgJm0N{4zKG6P NUntPYRGOjV|MEi5NVY>
SK-N-AS NHPzbWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDKUWU1OjUkgJno NFnEUYZKSzVyPUO3MlHjiIoEsfMAjVIvPCCwTR?= NYDkRZh1OjV|MEi5NVY>
SK-N-DZ M3LMS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPxXGwzPOLCiXi= NUXueYc2UUN3ME2xO{4y6oDLwsJihKkxNjRibl2= NF3peXEzPTNyOEmxOi=>
Caki-1 NXPX[YpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjjZ2cyOC9{NT:1NEBvVQ>? M4HWdVQ5KGh? Mnv3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{ MofUNlUzPzlzOUG=
ACHN MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY[xNE8zPS93MDDuUS=> MV60PEBp NHHoPYdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= NXvTRZVlOjV{N{mxPVE>
769-P NE\yWFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYOxNE8zPS93MDDuUS=> MlzhOFghcA>? MlPlbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{ MmHPNlUzPzlzOUG=
786-O  NFu5bIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LESVExNzJ3L{WwJI5O Mn3ROFghcA>? NITifIRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= Ml7SNlUzPzlzOUG=
Caki-1 NH7kPJJCeG:ydH;zbZMhSXO|YYm= M4HTOlUxKG6P NYfmW2I1PDhiaB?= M{jOdolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{ NHv0boozPTJ5OUG5NS=>
ACHN MYjBdI9xfG:|aYOgRZN{[Xl? NVj3SoN3PTBibl2= M2niSlQ5KGh? NIrpNYlqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= NIntPW8zPTJ5OUG5NS=>
769-P NE\ifHRCeG:ydH;zbZMhSXO|YYm= M{HlclUxKG6P NY\jc4JuPDhiaB?= NE\tV|VqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= NWTHNFhjOjV{N{mxPVE>
786-O  MofsRZBweHSxc3nzJGF{e2G7 MVK1NEBvVQ>? Mn3HOFghcA>? NGDUc|ZqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= M4LTO|I2Ojd7MUmx
Caki-1 NVLxWVBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTKNlUwPTBibl2= MVO0PEBp NX\adlJwTE2VTx?= NIjzV|hqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni MWqyOVE4PjN3NB?=
ACHN MlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXOyOU82OCCwTR?= NVPVcldqPDhiaB?= NI\DNJNFVVOR M{DqbIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK= NYOzUYZoOjVzN{[zOVQ>
769-P NHewNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[zUlI2NzVyIH7N NEnsfYI1QCCq NInzPYdFVVOR NXzjWmJ3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=> NGn4UpAzPTF5NkO1OC=>
Caki-1 M2DMcWNwdG:weTDGc5Ju[XSrb36gRZN{[Xl? MmrvOVAhdk1? M4fCZVcuOTRiZB?= M2nrSmROW09? NVmxdIxVe3WycILld5Nm\CClb3zvcpkh\m:{bXH0bY9vKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC5aYToJIJwenSnen;tbYIhyqB? NUD4[FdCOjVzN{[zOVQ>
ACHN NUPPOWhMS2:ub375JGZwem2jdHnvckBCe3OjeR?= MUS1NEBvVQ>? MmjZO{0yPCCm NW\Fc|M1TE2VTx?= MXHzeZBxemW|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=> MoLmNlUyPzZ|NUS=
769-P M2HSbmNwdG:weTDGc5Ju[XSrb36gRZN{[Xl? MoDhOVAhdk1? MWi3MVE1KGR? MV7EUXNQ MoXyd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> M2rU[VI2OTd4M{W0
Caki-1 M4TqfmFxd3C2b4Ppd{BCe3OjeR?= MmPqOVAhdk1? NUjBcXR3PDhiaB?= MVfEUXNQ MnvrbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MmjvNlUyPzZ|NUS=
ACHN MVLBdI9xfG:|aYOgRZN{[Xl? NID5NZo2OCCwTR?= M1\kdVQ5KGh? M{\LVmROW09? M361bolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? Mk\BNlUyPzZ|NUS=
769-P M37MV2Fxd3C2b4Ppd{BCe3OjeR?= MoTtOVAhdk1? NVXk[JJvPDhiaB?= MWDEUXNQ M16wTolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MnPyNlUyPzZ|NUS=
MDA-MB-231 MnjtUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6 NWj6dG9FOTEEoH7N MVqzxsBl Ml;5SG1UVw>? NX;qOm82[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg M3\aWVI1QDFyNEm3
BT-549 MVzNc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk> NYW5Nms6OTEEoH7N M2riSlPDqGR? NWHyOFhwTE2VTx?= NGq1Z5JidHSncoOgZ4VtdCCvb4LwbI9td2e7wrC= MlTnNlQ5OTB2OUe=
MCF-7  MnfQUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6 MXqxNOKhdk1? MYCzxsBl MmrQSG1UVw>? MWThcJRmenNiY3XscEBud3KyaH;sc4d6yqB? MlmwNlQ5OTB2OUe=
MCF-7 MVfGeY5kfGmxbjDBd5NigQ>? MknnOU02OCCwTR?= M1iyPVI1KGh? MorISG1UVw>? M{nZVZJm\HWlZXSgeIhmKGyndnXsJI9nKGW6cILld5Nqd25ib3[gSXLPuSxiUGKgZY5lKE[xeFGxxsA> MUOyOFM3PjRyNx?=
CTS M{j0PWFxd3C2b4Ppd{BCe3OjeR?= MVuw5qCUPDBibl5CpC=> MYK0PEBp MV;pcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MmLpNlQzPDR2Mkm=
OCI-AML3  MUfBdI9xfG:|aYOgRZN{[Xl? NXu3eoxuOOLCk{SwJI5OyqB? M3K3[|Q5KGh? NEm5d4lqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NHXPfWszPDJ2NESyPS=>
U937 MX3BdI9xfG:|aYOgRZN{[Xl? NYf2ZmZZOOLCk{SwJI5OyqB? M{HYTlQ5KGh? MmHWbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NUHBS2ZJOjR{NES0Nlk>
PC3 M2njN2Fxd3C2b4Ppd{BCe3OjeR?= NVzvPFBGOC1zMECgcm0> NIqxXFIzPC92ODDo NW\2R|BicW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NX7xW3l5OjRzNkOyN|A>
PC3-AR MYTBdI9xfG:|aYOgRZN{[Xl? NUfIOoxLOC1zMECgcm0> NYK5[W9LOjRxNEigbC=> MnfhbY5lfWOnczDhdI9xfG:|aYOgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz M16zTVI1OTZ|MkOw
PC3 NW\6SYJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGS2NZoxNTFyMDDuUS=> MV[yOE81QCCq NXLmWWd6cW6mdXPld{Bi[2O3bYXsZZRqd25ib3[gd5VjTzFicH;weYxifGmxbh?= MlLqNlQyPjN{M{C=
PC3-AR M1XEbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITtO4wxNTFyMDDuUS=> NVHQNXhWOjRxNEigbC=> NED0SXZqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKHSqZTDHNm0heGijc3W= MV2yOFE3OzJ|MB?=
PC3 M1zhb2Z2dmO2aX;uJGF{e2G7 M4\yTFAuOTByIH7N MUmyOEBp MWPzeZBxemW|c3XzJIV5eHKnc4Ppc44hd2ZiYXP0bZZifGWmIFHUUUwhSWu2IHHu[EBGemtzL{KgdJJwfGWrbh?= NXvF[3BuOjRzNkOyN|A>
PC3-AR NFrYd3BHfW6ldHnvckBCe3OjeR?= MlrDNE0yODBibl2= M{PwbVI1KGh? NHThXYl{fXCycnXzd4V{KGW6cILld5Nqd25ib3[gZYN1cX[jdHXkJGFVVSxiQXv0JIFv\CCHcnuxM|IheHKxdHXpci=> MV6yOFE3OzJ|MB?=
OS-RC-2 NH2xVlBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4C4W|AuOTByMDDuUS=> Mo\jNlQwPDhxN{KgbC=> M17r[2ROW09? NHfxXVJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz MlnpNlQyPDR5M{e=
OS-RC-2 M1zwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHT5R5E2OCCwTR?= NETXU2g1QCCq M2fqNmROW09? M3P4bIlv\HWlZYOgS|IwVSCjcoLld5Q> NG[0UG4zPDF2NEezOy=>
OS-RC-2 MnrLRZBweHSxc3nzJGF{e2G7 MWW1NEBvVQ>? NUPVNYFOPDhiaB?= MXnEUXNQ NHPhTHhqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M{ixV|I1OTR2N{O3
SK-N-AS MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnuT|Ux6oDVOECgcm0> NXTPUlU5PDhiaB?= NGTLWlZKSzVyPUK3MlQhdk1? NXLkNVl[OjRyOUi3PVk>
SK-N-DZ MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljlNQKBmzhyIH7N M4jvS|Q5KGh? NV21dmRjUUN3ME2yNU46KG6P M3fyTlI1ODl6N{m5
SK-N-SH MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIqzPGwx6oDVOECgcm0> NITvcpA1QCCq M{HB[mlEPTB;N{KuN{BvVQ>? NH[4[nIzPDB7OEe5PS=>
SK-N-BE NWiye|ZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3u1U|DjiJN6MDDuUS=> MVK0PEBp M2XUc2lEPTB;N{WuOEBvVQ>? NWnaWpFnOjRyOUi3PVk>
SK-N-AS NYPoR4hGSXCxcITvd4l{KEG|c3H5 M{e0VVDjiJN6MDDuUS=> M4LN[lQ5KGh? Mn;FdI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u MnX1NlQxQTh5OUm=
SK-N-DZ NEDUZWNCeG:ydH;zbZMhSXO|YYm= MmP0NQKBmzhyIH7N MojDOFghcA>? NXLpZ4tJeG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v MonLNlQxQTh5OUm=
SK-N-SH MXLBdI9xfG:|aYOgRZN{[Xl? NVX4dIJCOOLCk{SwJI5O NWi2NYVRPDhiaB?= NFTzVZFxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> M1HCSFI1ODl6N{m5
SK-N-BE NHTpRXdCeG:ydH;zbZMhSXO|YYm= MV6w5qCUPDBibl2= MUK0PEBp NF72W5hxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> NIPZU|AzPDB7OEe5PS=>
SK-N-AS NGHne4pHfW6ldHnvckBCe3OjeR?= NWKxeVZ2OOLCk{iwJI5O NUO1XHM5PDhiaB?= Mnf3bY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> NIHUNmwzPDB7OEe5PS=>
SK-N-DZ NVS0[5BkTnWwY4Tpc44hSXO|YYm= NVnzXGhlOOLCk{iwJI5O M13JO|Q5KGh? M2K5PIlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> MlrINlQxQTh5OUm=
SK-N-SH MlznSpVv[3Srb36gRZN{[Xl? NV\qOJg4OOLCk{SwJI5O MXi0PEBp M1;JdIlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> MnXDNlQxQTh5OUm=
SK-N-BE NY\yTpI1TnWwY4Tpc44hSXO|YYm= MXiw5qCUPDBibl2= NWXWV|ZTPDhiaB?= MnvKbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> NIm2N5QzPDB7OEe5PS=>
HCC-LM3 NWH3cZZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq4NU0yODByIH7N MoTLNlQwPDhxN{KgbC=> NWTleZlqTE2VTx?= MUjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MoXkNlQxQTN7NU[=
HepG2 M3W1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnf3NU0yODByIH7N MkTqNlQwPDhxN{KgbC=> MXLEUXNQ NGXRTmVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGL5SGwzPDB7M{m1Oi=>
SMMC-7721 NIXnU|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDGNU0yODByIH7N MnmzNlQwPDhxN{KgbC=> MUHEUXNQ MWTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NEHk[oQzPDB7M{m1Oi=>
HCC-LM3 MULBdI9xfG:|aYOgRZN{[Xl? Mlq4OVAhdk1? NG[1VIg1QCCq NYXNe497TE2VTx?= MmLCbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk> Mo\6NlQxQTN7NU[=
HepG2 Ml:4RZBweHSxc3nzJGF{e2G7 MnHMOVAhdk1? NXX5RZV2PDhiaB?= NFjwSWRFVVOR NEC4SHZqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMhOyxiODDhcoQhQQ>? M2LBXlI1ODl|OUW2
SMMC-7721 MVvBdI9xfG:|aYOgRZN{[Xl? M1PLbFUxKG6P NVL1flY4PDhiaB?= NFfjcmJFVVOR NYjjTllrcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl? MVGyOFA6Ozl3Nh?=
HCC-LM3 MlTISpVv[3Srb36gRZN{[Xl? NHO1TlQ2OC9zMECgcm0> M3P4dFI1KGh? NHzQSm1FVVOR Mkj0[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?= MWCyOFA6Ozl3Nh?=
HepG2 NGTzOVVHfW6ldHnvckBCe3OjeR?= MWi1NE8yODBibl2= Mmr6NlQhcA>? NIXrZZlFVVOR NEnNVlZl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR|IHHu[EBxNUGtdNMg MYqyOFA6Ozl3Nh?=
SMMC-7721 MlnKSpVv[3Srb36gRZN{[Xl? NYK4OWZiPTBxMUCwJI5O MUeyOEBp NWTiNmlwTE2VTx?= M4nLPYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC= M{XwNVI1ODl|OUW2
HCC-LM3 NHPJbVJHfW6ldHnvckBCe3OjeR?= NV\NcGU1PTBxMUCwJI5O NUezfY9JOjRiaB?= MXvEUXNQ NUnQeoxz\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= NUPCWGNLOjRyOUO5OVY>
HepG2 MWPGeY5kfGmxbjDBd5NigQ>? Mn3mOVAwOTByIH7N Ml\KNlQhcA>? NYLYRnl4TE2VTx?= NVS5cGxw\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= MknYNlQxQTN7NU[=
SMMC-7721 MWHGeY5kfGmxbjDBd5NigQ>? M2fEfVUxNzFyMDDuUS=> MXOyOEBp NHnkRWdFVVOR NX\Bb3Bk\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= NVTDWWs3OjRyOUO5OVY>
FaDu M{LDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XJN|ExOOLChX7N MVe4M|ExNzF{IHi= NUf4fXY2\Gm|cHzhfYVlKGFic3nncolncWOjboSgZY5lKHC{b3zvcodm\CCJMj;NJIFzemW|dDDheEA5KGGwZDCxNwKBjWhicH;zeEBz\WynYYPl NVT1eGI1OjRyMk[0PFI>
FaDu NXza[GFTTnWwY4Tpc44hSXO|YYm= M{\lXFExOOLChX7N MVSyM|QwQC9zMjDo MXPpcoR2[2WmIICyNXdi\jFxQ3nwNeKh\XiycnXzd4lwdg>? NFLESoQzPDB{NkS4Ni=>
PC-3  MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfEWlhMOC1zMDFOwG0> MnfKNlQwPDhxN{KgbC=> M3LENolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mk[1NlM6QTF{MU[=
LNCaP M3ztUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nPV|AuPSEQvF2= MoDGNlQwPDhxN{KgbC=> MoDKbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NUfEVZlQOjN7OUGyNVY>
RWPE-1  M3jsemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3OwSlAuOjBizszN MYKyOE81QC95MjDo M{jLTYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NGfEeWUzOzl7MUKxOi=>
Capan-1 NVrxWJU2TnWwY4Tpc44hSXO|YYm= MUiyOU82OC9zMECgcm0> MknqPE8zPC92ODDo NYLnW3dFTE2VTx?= Mkjt[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?= Mn;HNlM6OjJ6OE[=
L3.6pl NUS2cpBRTnWwY4Tpc44hSXO|YYm= Mlj3NlUwPTBxMUCwJI5O NV;HVHpsQC9{ND:0PEBp NFfFc5JFVVOR MX;kc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p NWTJUWl6OjN7MkK4PFY>
CFPAC-1  NFzRXYRHfW6ldHnvckBCe3OjeR?= NV22dYZtOjVxNUCvNVAxKG6P NVTVbo15QC9{ND:0PEBp MmKzSG1UVw>? MUHkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p M{O2dFI{QTJ{OEi2
Capan-1 NEHSUmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13LZVI2NzVyL{GwNEBvVQ>? MoDoOFghcA>? NYjsUmtHTE2VTx?= NEezbHdz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmfaNlM6OjJ6OE[=
L3.6pl NYXPOGZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzUNlUwPTBxMUCwJI5O NGi4XVM1QCCq NUH2SIxSTE2VTx?= MoO3doVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MmTHNlM6OjJ6OE[=
CFPAC-1  NIjYb4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnvNphnOjVxNUCvNVAxKG6P M3fuZlQ5KGh? MkjBSG1UVw>? NHfLRpFz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NI[zT5UzOzl{Mki4Oi=>
Capan-1 NXrj[HR5SXCxcITvd4l{KEG|c3H5 Ml3pNlUwPTBxMUCwJI5O MVW0PEBp M122W2ROW09? MkPrbY5lfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M2q1dVI{QTJ{OEi2
L3.6pl MkjORZBweHSxc3nzJGF{e2G7 NXL3V|NROjVxNUCvNVAxKG6P MXy0PEBp MnTjSG1UVw>? MWPpcoR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NIP1[WUzOzl{Mki4Oi=>
CFPAC-1  M1\yXGFxd3C2b4Ppd{BCe3OjeR?= NIP0d48zPS93MD:xNFAhdk1? NEe0cHM1QCCq NEH3VpJFVVOR MUjpcoR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MkSxNlM6OjJ6OE[=
HN22 Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfXNE0zOCCwTR?= MlPMNlQwPDhiaB?= NEfveodFVVOR NInZ[W5qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz MYKyN|g4PzJ|NR?=
HSC4  NV60SlM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWGwMVIxKG6P MVKyOE81QCCq MUjEUXNQ Ml\2bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> NFW2bGszOzh5N{KzOS=>
HN22 M1jMOWFxd3C2b4Ppd{BCe3OjeR?= NGLMfIgxNTJyIH7N MYi0PEBp MoT3SG1UVw>? M37LOIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NWrPPZhIOjN6N{eyN|U>
HSC4  MonMRZBweHSxc3nzJGF{e2G7 NYW1fWh4OC1{MDDuUS=> MljoOFghcA>? NYe5TZJ[TE2VTx?= M2\R[4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NU\RVlRkOjN6N{eyN|U>
HN22 MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX2wMVIxKG6P MVS0PEBp NIG5Z4dFVVOR NIS3[nBqdmS3Y3XzJGcyKHCqYYPlJINmdGxiY4njcIUh[XK{ZYP0xsA> MYmyN|g4PzJ|NR?=
HSC4  MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljmNE0zOCCwTR?= MYG0PEBp MojSSG1UVw>? MlPtbY5lfWOnczDHNUBxcGG|ZTDj[YxtKGO7Y3zlJIFzemW|dNMg NVXkdIFqOjN6N{eyN|U>
HN22 Mmn4SpVv[3Srb36gRZN{[Xl? Mnu0NE0zOCCwTR?= MnP0OFghcA>? NYPaW3lFTE2VTx?= NH3IdIJ{fXCycnXzd4V{KFOyMTDlfJBz\XO|aX;uxsA> NV\tdZBmOjN6N{eyN|U>
HSC4  NV;1U2QxTnWwY4Tpc44hSXO|YYm= NXPJcJNEOC1{MDDuUS=> Ml7xOFghcA>? M3rET2ROW09? M4GzeZN2eHC{ZYPz[ZMhW3BzIHX4dJJme3Orb39CpC=> Ml74NlM5Pzd{M{W=
Cal62 Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\0c|hXUUN3ME2zN{DDuSB2IH7N MYKyN|gzPDB4NB?=
Hth7 M2jXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TS[GlEPTB;MUWgxtEhOiCwTR?= Mn75NlM5OjRyNkS=
Hth83 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLkTWM2OD1|NDFCtUA2KG6P M1XYVlI{QDJ2ME[0
C643 NIHlcJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\FRmlEPTB;N{GgxtEhOTBibl2= NFXkOGMzOzh{NEC2OC=>
SW1736 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXZTHBKSzVyPUO1JOKyKDhibl2= MmnKNlM5OjRyNkS=
T241 NUHkfYJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvKTWM2OD14NTFCtUA4KG6P NXzueYxFOjN6MkSwOlQ>
T351 NYTlXIs3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTVyINMxJFExKG6P M330NlI{QDJ2ME[0
BHP2-7 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLTT3JJUUN3ME2zO{DDuSB4IH7N M2D5dFI{QDJ2ME[0
T238 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrBXGhKSzVyPUGsOVAxKMLzIEKwNEBvVQ>? NGSxeFMzOzh{NEC2OC=>
HCT8 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M136b|czKGh? NYD4N5FETE2VTx?= NVLWUZlmUUN3ME2xNk466oDLwsJihKkyNjlibl2= MVGyN|I6QTN6OB?=
H630 NFLMVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rydVczKGh? NHHZUItFVVOR NXzUS4RtUUN3ME2xNk416oDLwsJihKk{NjFibl2= MmDwNlMzQTl|OEi=
cH630 5-FU-res NV3lWGdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInaUYQ4OiCq M4fU[mROW09? NIjWblVKSzVyPUG1MlXjiIoEsfMAjVEvOiCwTR?= NUDYelRQOjN{OUmzPFg>
HCT116 M{TDNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\aO|IhcA>? MkjuSG1UVw>? NYjGWVllUUN3ME2xNE446oDLwsJihKkzNjJibl2= MWSyN|I6QTN6OB?=
HCT116 p53−/− M4DiNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYi3NkBp NELHfZpFVVOR MlXFTWM2OD16LkdihKnDueLCiUGuO{BvVQ>? M1\1clI{Ojl7M{i4
dHCT116 p21−/− MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37vNlczKGh? NGLM[G9FVVOR NUPx[JpuUUN3ME21MlnjiIoEsfMAjVEvOyCwTR?= NV7TS5REOjN{OUmzPFg>
HT29 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\IO|IhcA>? MofESG1UVw>? M3e0NGlEPTB;MU[uN-KBkcLz4pEJNk4{KG6P NVXaVHNoOjN{OUmzPFg>
LoVo MkDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnKxO|IhcA>? MY\EUXNQ MYTJR|UxRTVwMfMAjeKy6oDLMD62JI5O NVvQdphVOjN{OUmzPFg>
RKO MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrBPIs4OiCq MmL6SG1UVw>? NUPq[mc3UUN3ME23MlnjiIoEsfMAjVIvOiCwTR?= M2TKOVI{Ojl7M{i4
SW480 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NET5TIE4OiCq M{PZT2ROW09? MWnJR|UxRTF5LkZihKnDueLCiUCuPEBvVQ>? NFm5XVUzOzJ7OUO4PC=>
eSW620 NWntR2FXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:1TFczKGh? M2fNWGROW09? MYPJR|UxRTlwMfMAjeKy6oDLMj6xJI5O MnvMNlMzQTl|OEi=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

お薦めの試験操作(参考用のみ)

細胞試験: [1]
+ 展開
  • 細胞株: MOLT-4 cell lines and Reh (pre-B cells)
  • 濃度: 50 nM
  • 反応時間: 48 hours
  • 実験の流れ: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • 製剤: Dextrose 5% in water
  • 投薬量: 10 mg/kg, 20 mg/kg
  • 投与方法: Administered via i.p. injection
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 349.43
化学式

C21H23N3O2

CAS No. 404950-80-7
保管
in solvent
別名 NVP-LBH589

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03632317 Recruiting Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Cancer Center September 2018 Phase 2
NCT03566199 Recruiting Diffuse Intrinsic Pontine Glioma Sabine Mueller MD PhD|Midatech Pharma US Inc.|Pacific Pediatric Neuro-Oncology Consortium|University of California San Francisco May 22 2018 Phase 1|Phase 2
NCT03256045 Recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma University of Washington|National Cancer Institute (NCI) February 8 2018 Phase 2
NCT02961816 Withdrawn Lymphoma M.D. Anderson Cancer Center June 2017 Phase 2
NCT02802163 Withdrawn Multiple Myeloma H. Lee Moffitt Cancer Center and Research Institute|Novartis|Amgen June 2017 Phase 1|Phase 2
NCT02756663 Withdrawn Multiple Myeloma Novartis Pharmaceuticals|Novartis December 2016 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    How to reconstitute the compound for in vivo mice study?

  • 回答:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Panobinostat (LBH589)を買う | Panobinostat (LBH589) ic50 | Panobinostat (LBH589)供給者 | Panobinostat (LBH589)を購入する | Panobinostat (LBH589)費用 | Panobinostat (LBH589)生産者 | オーダーPanobinostat (LBH589) | Panobinostat (LBH589)化学構造 | Panobinostat (LBH589)分子量 | Panobinostat (LBH589)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID